Please use this identifier to cite or link to this item:
Title: European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission
Authors: Lawler, Mark 
Davies, Lynne 
Oberst, Simon 
Oliver, Kathy 
Eggermont, Alexander 
Schmutz, Anna 
La Vecchia, Carlo 
Allemani, Claudia 
Lievens, Yolande 
Naredi, Peter 
Cufer, Tanja 
Aggarwal, Ajay 
Aapro, Matti 
Apostolidis, Kathi 
Baird, Anne-Marie 
Cardoso, Fatima 
Charalambous, Andreas 
Coleman, Michel P 
Costa, Alberto 
Crul, Mirjam 
Csaba, Degi L. 
Di Nicolantonio, Federica 
Erdem, Sema 
Geanta, Marius 
Geissler, Jan 
Jassem, Jacek 
Jagielska, Beata 
Jonsson, Bengt 
Kelly, Daniel 
Kelm, Olaf 
Kolarova, Teodora 
Kutluk, Tezer 
Lewison, Grant 
Meunier, Françoise 
Pelouchova, Jana 
Philip, Thierry 
Price, Richard 
Rau, Beate 
Rubio, Isabel T 
Selby, Peter 
Južnič Sotlar, Maja 
Spurrier-Bernard, Gilliosa 
van Hoeve, Jolanda C 
Vrdoljak, Eduard 
Westerhuis, Willien 
Wojciechowska, Urszula 
Sullivan, Richard 
Major Field of Science: Medical and Health Sciences
Keywords: The Lancet Oncology Commission;Review and Opinion
Issue Date: 24-Jan-2023
Source: The Lancet Oncology, 2023, vol. 24, no. 1, pp. 11-56
Volume: 24
Issue: 1
Start page: 11
End page: 56
Journal: The Lancet Oncology 
Abstract: Cancer research is a crucial pillar for countries to deliver more affordable, higher quality, and more equitable cancer care. Patients treated in research-active hospitals have better outcomes than patients who are not treated in these settings. However, cancer in Europe is at a crossroads. Cancer was already a leading cause of premature death before the COVID-19 pandemic, and the disastrous effects of the pandemic on early diagnosis and treatment will probably set back cancer outcomes in Europe by almost a decade. Recognising the pivotal importance of research not just to mitigate the pandemic today, but to build better European cancer services and systems for patients tomorrow, the Lancet Oncology European Groundshot Commission on cancer research brings together a wide range of experts, together with detailed new data on cancer research activity across Europe during the past 12 years. We have deployed this knowledge to help inform Europe's Beating Cancer Plan and the EU Cancer Mission, and to set out an evidence-driven, patient-centred cancer research roadmap for Europe. The high-resolution cancer research data we have generated show current activities, captured through different metrics, including by region, disease burden, research domain, and effect on outcomes. We have also included granular data on research collaboration, gender of researchers, and research funding. The inclusion of granular data has facilitated the identification of areas that are perhaps overemphasised in current cancer research in Europe, while also highlighting domains that are underserved. Our detailed data emphasise the need for more information-driven and data-driven cancer research strategies and planning going forward. A particular focus must be on central and eastern Europe, because our findings emphasise the widening gap in cancer research activity, and capacity and outcomes, compared with the rest of Europe. Citizens and patients, no matter where they are, must benefit from advances in cancer research. This Commission also highlights that the narrow focus on discovery science and biopharmaceutical research in Europe needs to be widened to include such areas as prevention and early diagnosis; treatment modalities such as radiotherapy and surgery; and a larger concentration on developing a research and innovation strategy for the 20 million Europeans living beyond a cancer diagnosis. Our data highlight the important role of comprehensive cancer centres in driving the European cancer research agenda. Crucial to a functioning cancer research strategy and its translation into patient benefit is the need for a greater emphasis on health policy and systems research, including implementation science, so that the innovative technological outputs from cancer research have a clear pathway to delivery. This European cancer research Commission has identified 12 key recommendations within a call to action to reimagine cancer research and its implementation in Europe. We hope this call to action will help to achieve our ambitious 70:35 target: 70% average 10-year survival for all European cancer patients by 2035.
ISSN: 14702045
DOI: 10.1016/S1470-2045(22)00540-X
Rights: Copyright © Elsevier Ltd
Type: Article
Affiliation : Queen’s University Belfast 
International Cancer Research Partnership 
Organisation of European Cancer Institutes 
International Brain Tumour Alliance 
European Cancer Organisation Patient Advisory Committee 
University Medical Center Utrecht 
Princess Máxima Centrum 
International Agency for Cancer Research 
Università degli Studi di Milano 
London School of Hygiene and Tropical Medicine 
Ghent University Hospital 
University of Gothenburg 
Sahlgrenska University Hospital 
University of Ljubljana 
London School of Hygiene and Tropical Medicine 
King's College London 
Genolier Cancer Center 
Guy’s and St Thomas’​ NHS Foundation Trust 
Genolier Cancer Center 
Hellenic Cancer Federation 
European Cancer Patient Coalition 
Lung Cancer Europe 
Trinity College Dublin 
Clinical Center Champalimaud 
European Cancer Organisation Brussels 
Cyprus University of Technology 
University of Turku 
European School of Oncology 
Amsterdam UMC 
Babeş-Bolyai University 
University of Turin 
Candiolo Cancer Institute 
Europa Donna 
Centre for Innovation in Medicine and Kol Medical Media 
Patvocates and CML Advocates Network 
Medical University of Gdansk 
Maria Skłodowska-Curie National Research Institute of Oncology 
Stockholm School of Economics 
School of Healthcare Sciences 
International Agency for Research on Cancer 
International Neuroendocrine Cancer Alliance 
Hacettepe University 
Belgian Royal Academy of Medicine 
Diagnoza leukemie 
Organisation of European Cancer Institutes 
Institut Curie 
European Cancer Organisation Brussels 
Charité-Universitätsmedizin Berlin 
Freie Universität Berlin 
Humboldt-Universitat zu Berlin 
University of Navarra 
University of Leeds 
EuropaColon Slovenia 
Melanoma Patient Network Europe 
Netherlands Comprehensive Cancer Organisation 
University of Split 
Appears in Collections:Άρθρα/Articles

CORE Recommender
Show full item record

Citations 10

checked on Mar 2, 2024


Last Week
Last month
checked on Nov 1, 2023

Page view(s) 10

Last Week
Last month
checked on Mar 3, 2024

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons